 |
|
Enoxaparin vs Unfractionated Heparin in Acute Coronary Syndrome—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: In response to Dr Pedrini and colleagues, we did not design our study to evaluate the important question of the duration of antithrombin therapy. Our protocol suggested a minimum duration of treatment with unfractionated or low-molecular-weight heparin of 48 hours, but treatment duration could be shortened for those undergoing early percutaneous intervention, with heparin discontinuation permitted 12 hours after intervention. Maximal duration for study-provided medications was limited to 120 hours by protocol. Although not based on data from randomized controlled trials, this strategy is consistent with American College of Cardiology/American Heart Association guideline recommendations.1
With respect to the points raised by Drs Kanna and Sharma, at 6 to 12 hours, 12 to 24 hours, and 24 to 48 hours, the proportions of individuals with subtherapeutic aPTT values were 39%, 43%, and 47%, respectively; with therapeutic aPTT values, 30%, 35%, and 35%; and with supratherapeutic aPTT values, 31%, 22%, . . . [Full Text of this Article]
Michael A. Blazing, MD
blazi001@mc.duke.edu
Duke Clinical Research Institute
Durham, NC
RELATED ARTICLES
Enoxaparin vs Unfractionated Heparin in Acute Coronary Syndrome
Michael Pedrini, Frank Hartig, and Christoph Pechlaner
JAMA. 2004;292(16):1952.
EXTRACT
| FULL TEXT
Enoxaparin vs Unfractionated Heparin in Acute Coronary Syndrome
Balavenkatesh Kanna and Puneeta Sharma
JAMA. 2004;292(16):1952.
EXTRACT
| FULL TEXT
Enoxaparin vs Unfractionated Heparin in Acute Coronary Syndrome—Reply
Kenneth W. Mahaffey, James J. Ferguson, Robert M. Califf, and for the SYNERGY Trial Investigators
JAMA. 2004;292(16):1952-1953.
EXTRACT
| FULL TEXT
|
